CAI
Caris Life Sciences
$24.04
+$0.01 (+0.04%)Sep 10, 2026
Key metrics
The numbers that frame CAI today
- Market cap
- $6.79B
- P/E (TTM)
- 64.6
- EV / FCF
- 52.4
- Gross margin
- 69.7%
- EV / Sales
- 6.6
- ROIC
- 25.9%
- Div yield
- 0%
- Debt / equity
- 0.7
- 52wk Low
- $14.19
- 52wk High
- $35.20
Growth
Revenue and earnings trend for CAI
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about CAI
Is Caris Life Sciences a good buy?
Yes. Caris Life Sciences has strong quality and mixed momentum. Taken together, the setup leans positive. Growth looks excellent, which supports the long-term business case. We think Caris Life Sciences is selling at a fair price.
What is the market capitalization of CAI?
Caris Life Sciences's market capitalization is $6.79B.
What is the P/E ratio for CAI stock?
Caris Life Sciences's current P/E ratio is 64.6.
What is the 52-week high for CAI stock?
The 52-week high for Caris Life Sciences is $35.20. The current close of $24.04 is 31.7% below that high.
What is the 52-week low for CAI stock?
The 52-week low for Caris Life Sciences is $14.19. The current close of $24.04 is 69.4% above that low.
Does CAI stock pay dividends?
Caris Life Sciences does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for CAI?
Caris Life Sciences's Debt / Equity ratio is 0.66.